share_log

Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14

Benzinga Real-time News ·  Feb 22, 2023 08:21

Roth MKM analyst Jonathan Aschoff initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment